Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04853329 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma
A Phase 1 study, sponsored by Conjupro Biotherapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT04853329 is a Phase 1 study that was terminated before completion, run by Conjupro Biotherapeutics. The registered enrollment target is 7 participants.
The verdict
NCT04853329, a Phase 1 study, was terminated before completion, sponsored by Conjupro Biotherapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This first-in-human Phase 1 study will be a multicenter, dose-escalating, single-agent study conducted in patients with advanced CD20-associated hematological cancers for which the investigator determines there to be no other higher priority therapies available.
Interventions
- DRUG CPO107
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-12-13 |
| Est. Completion | 2023-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04853329
The ClinicalTrials.gov registry entry for NCT04853329 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Conjupro Biotherapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CPO107 is the first listed.
NCT04853329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04853329 about?
NCT04853329 is a clinical study titled "Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma". This first-in-human Phase 1 study will be a multicenter, dose-escalating, single-agent study conducted in patients with advanced CD20-associated hematological cancers for which the investigator determines there to be no other higher priority therapies available.
What is the current status of trial NCT04853329?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2021-12-13. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT04853329?
The interventions under investigation include: CPO107 (DRUG).
Who is sponsoring clinical trial NCT04853329?
This trial is sponsored by Conjupro Biotherapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.